These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 33512414)

  • 21. Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed/refractory large B-cell lymphoma in China.
    Ying Z; Yang H; Guo Y; Li W; Zou D; Zhou D; Wang Z; Zhang M; Wu J; Liu H; Zhang P; Yang S; Zhou Z; Zheng H; Song Y; Zhu J
    Cancer Med; 2021 Feb; 10(3):999-1011. PubMed ID: 33382529
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy.
    Kochenderfer JN; Somerville RPT; Lu T; Yang JC; Sherry RM; Feldman SA; McIntyre L; Bot A; Rossi J; Lam N; Rosenberg SA
    Mol Ther; 2017 Oct; 25(10):2245-2253. PubMed ID: 28803861
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies.
    Liang Y; Liu H; Lu Z; Lei W; Zhang C; Li P; Liang A; Young KH; Qian W
    J Hematol Oncol; 2021 Feb; 14(1):26. PubMed ID: 33593414
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma.
    Yan ZX; Li L; Wang W; OuYang BS; Cheng S; Wang L; Wu W; Xu PP; Muftuoglu M; Hao M; Yang S; Zhang MC; Zheng Z; Li J; Zhao WL
    Clin Cancer Res; 2019 Dec; 25(23):6995-7003. PubMed ID: 31444250
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
    Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
    Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Allogeneic CD19/CD22 CAR T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia.
    Phely L; Hensen L; Faul C; Ruff CA; Schneider D; Bethge WA; Lengerke C
    JAMA Oncol; 2024 Jun; 10(6):821-824. PubMed ID: 38635232
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma.
    Locke FL; Neelapu SS; Bartlett NL; Siddiqi T; Chavez JC; Hosing CM; Ghobadi A; Budde LE; Bot A; Rossi JM; Jiang Y; Xue AX; Elias M; Aycock J; Wiezorek J; Go WY
    Mol Ther; 2017 Jan; 25(1):285-295. PubMed ID: 28129122
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Engineering Novel CD19/CD22 Dual-Target CAR-T Cells for Improved Anti-Tumor Activity.
    Zeng W; Zhang Q; Zhu Y; Ou R; Peng L; Wang B; Shen H; Liu Z; Lu L; Zhang P; Liu S
    Cancer Invest; 2022 Mar; 40(3):282-292. PubMed ID: 34797742
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy.
    Iqbal M; Jagadeesh D; Chavez J; Khurana A; Rosenthal A; Craver E; Epperla N; Li Z; Isufi I; Awan FT; Dholaria BR; Maakaron JE; Sandoval-Sus JD; Mishra R; Saha A; Annunzio K; Bhaskar ST; Sumransub N; Fijalka A; Ivanov SA; Lin Y; Kharfan-Dabaja MA
    Bone Marrow Transplant; 2024 Feb; 59(2):211-216. PubMed ID: 37973893
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy.
    Chong EA; Alanio C; Svoboda J; Nasta SD; Landsburg DJ; Lacey SF; Ruella M; Bhattacharyya S; Wherry EJ; Schuster SJ
    Blood; 2022 Feb; 139(7):1026-1038. PubMed ID: 34496014
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1-2 trial.
    Zhang Y; Wang Y; Liu Y; Tong C; Wang C; Guo Y; Ti D; Yang Q; Qiao S; Wu Z; Han W
    Leukemia; 2022 Jan; 36(1):189-196. PubMed ID: 34272481
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD19/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell Lymphomas.
    Cao Y; Xiao Y; Wang N; Wang G; Huang L; Hong Z; Meng L; Zhou X; Wang J; Yang Y; Xu H; Zhang S; Xiao M; Chen L; Zheng M; Li C; Mao X; Gu C; Zhang T; Zhang Y; Zhou J
    Transplant Cell Ther; 2021 Nov; 27(11):910.e1-910.e11. PubMed ID: 34425260
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD19-directed CAR T-cell therapy in B-cell NHL.
    Kersten MJ; Spanjaart AM; Thieblemont C
    Curr Opin Oncol; 2020 Sep; 32(5):408-417. PubMed ID: 32740094
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    Li C; Sun Y; Wang J; Tang L; Jiang H; Guo T; Liu L; Wu Y; Ai L; Xia L; Wu J; Lin Z; Qian Q; Hu Y; Mei H
    Front Immunol; 2021; 12():599493. PubMed ID: 34113336
    [TBL] [Abstract][Full Text] [Related]  

  • 35. T Cell Defects: New Insights Into the Primary Resistance Factor to CD19/CD22 Cocktail CAR T-Cell Immunotherapy in Diffuse Large B-Cell Lymphoma.
    Wang J; Shen K; Mu W; Li W; Zhang M; Zhang W; Li Z; Ge T; Zhu Z; Zhang S; Chen C; Xing S; Zhu L; Chen L; Wang N; Huang L; Li D; Xiao M; Zhou J
    Front Immunol; 2022; 13():873789. PubMed ID: 35572515
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels.
    Kochenderfer JN; Somerville RPT; Lu T; Shi V; Bot A; Rossi J; Xue A; Goff SL; Yang JC; Sherry RM; Klebanoff CA; Kammula US; Sherman M; Perez A; Yuan CM; Feldman T; Friedberg JW; Roschewski MJ; Feldman SA; McIntyre L; Toomey MA; Rosenberg SA
    J Clin Oncol; 2017 Jun; 35(16):1803-1813. PubMed ID: 28291388
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.
    Cappell KM; Sherry RM; Yang JC; Goff SL; Vanasse DA; McIntyre L; Rosenberg SA; Kochenderfer JN
    J Clin Oncol; 2020 Nov; 38(32):3805-3815. PubMed ID: 33021872
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Coadministration of CD19- and CD22-Directed Chimeric Antigen Receptor T-Cell Therapy in Childhood B-Cell Acute Lymphoblastic Leukemia: A Single-Arm, Multicenter, Phase II Trial.
    Wang T; Tang Y; Cai J; Wan X; Hu S; Lu X; Xie Z; Qiao X; Jiang H; Shao J; Yang F; Ren H; Cao Q; Qian J; Zhang J; An K; Wang J; Luo C; Liang H; Miao Y; Ma Y; Wang X; Ding L; Song L; He H; Shi W; Xiao P; Yang X; Yang J; Li W; Zhu Y; Wang N; Gu L; Chen Q; Tang J; Yang JJ; Cheng C; Leung W; Chen J; Lu J; Li B; Pui CH
    J Clin Oncol; 2023 Mar; 41(9):1670-1683. PubMed ID: 36346962
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CAR T cell therapy for B-cell lymphomas.
    Chavez JC; Locke FL
    Best Pract Res Clin Haematol; 2018 Jun; 31(2):135-146. PubMed ID: 29909914
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy?
    Liu S; Zhang X; Dai H; Cui W; Yin J; Li Z; Yang X; Yang C; Xue S; Qiu H; Miao M; Chen S; Jin Z; Fu C; Li C; Sun A; Han Y; Wang Y; Yu L; Wu D; Cui Q; Tang X
    Blood Cancer J; 2023 Apr; 13(1):60. PubMed ID: 37095120
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.